Resof-L Tablet is a prescription medication used for the treatment of chronic hepatitis C virus (HCV) infection. It combines two antiviral agents: Ledipasvir (90 mg) and Sofosbuvir (400 mg). Ledipasvir is an NS5A inhibitor that interferes with a protein essential for viral replication, while Sofosbuvir is a nucleotide polymerase inhibitor targeting the NS5B protein, crucial for viral RNA synthesis. Together, they work synergistically to reduce and eliminate HCV from the bloodstream.
The standard dosage is one tablet taken orally once daily, with or without food. It is important to take the medication at the same time each day to maintain consistent blood levels. Adherence to the full course of treatment, typically lasting 12 to 24 weeks depending on individual factors such as HCV genotype and the presence of cirrhosis, is crucial to achieve optimal outcomes.
Common side effects of Resof-L include fatigue and headache. Most adverse effects are mild and manageable. Patients should inform their healthcare provider of all medications they are taking to avoid potential drug interactions. Regular monitoring during treatment is recommended to assess efficacy and detect any adverse effects promptly.
Resof-L has significantly improved HCV treatment outcomes, offering a high cure rate with a convenient, once-daily oral regimen. Consultation with a healthcare professional is essential to determine the most appropriate treatment plan based on individual patient factors.
Reviews
There are no reviews yet.